Skip to Content

Alk-Abello A/S Class B ALK B

Morningstar Rating
DKK 124.10 +0.20 (0.16%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ALK B is trading at a 14% premium.
Price
DKK 125.08
Fair Value
DKK 954.57
Uncertainty
High
1-Star Price
DKK 472.48
5-Star Price
DKK 75.85
Economic Moat
Tzlbtwl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALK B is a good fit for your portfolio.

Trading Information

Previous Close Price
DKK 123.90
Day Range
DKK 122.10124.30
52-Week Range
DKK 69.90134.50
Bid/Ask
DKK 123.60 / DKK 123.90
Market Cap
DKK 27.45 Bil
Volume/Avg
254,733 / 308,351

Key Statistics

Price/Earnings (Normalized)
53.82
Price/Sales
5.69
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
2,752

Comparables

Valuation

Metric
ALK B
ZEAL
TLX
Price/Earnings (Normalized)
53.82101.49
Price/Book Value
6.1724.9828.02
Price/Sales
5.69112.508.28
Price/Cash Flow
31.56172.26
Price/Earnings
ALK B
ZEAL
TLX

Financial Strength

Metric
ALK B
ZEAL
TLX
Quick Ratio
1.066.231.19
Current Ratio
2.266.251.43
Interest Coverage
29.86−29.301.15
Quick Ratio
ALK B
ZEAL
TLX

Profitability

Metric
ALK B
ZEAL
TLX
Return on Assets (Normalized)
7.86%−27.82%3.71%
Return on Equity (Normalized)
12.08%−38.14%11.73%
Return on Invested Capital (Normalized)
10.49%−33.13%18.08%
Return on Assets
ALK B
ZEAL
TLX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRZxyhptdyvCzrh$570.1 Bil
VRTX
Vertex Pharmaceuticals IncMxgnhzjmPvrhsn$108.0 Bil
REGN
Regeneron Pharmaceuticals IncVqyhhgttTpswbfd$105.6 Bil
MRNA
Moderna IncVcfjfllPjc$40.8 Bil
ARGX
argenx SE ADRWpbycmyHvyx$23.5 Bil
BNTX
BioNTech SE ADRRxrdwcjjCmz$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncVfkfpwjzSpnrbf$18.8 Bil
BMRN
Biomarin Pharmaceutical IncKccvqvqYzrxtb$16.5 Bil
RPRX
Royalty Pharma PLC Class ABtvwyfmdZmfbr$13.6 Bil
INCY
Incyte CorpWlhvjxxyJfszpf$12.8 Bil

Sponsor Center